Back to GSKView full pipeline
Phase 3
Development Phase
0
Upcoming Catalysts
0
Historical Events
1
Regulatory Approvals
No Catalysts Found
No catalyst events have been recorded for this drug yet.
Competitive Landscape
2 competitors in Pulmonary Disease, Chronic Obstructive
View Full LandscapeDrug Information
Target Indication
Pulmonary Disease, Chronic Obstructive
Clinical Trial
NCT01772134Last updated: 1/24/2026
Patent & Exclusivity
No patent data available. Pre-approval drugs may not have Orange Book listings.
Regulatory Approvals
EMA4/28/2014
Incruse Ellipta (previously Incruse)
Indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD).
View on EMADrug Science
Mechanism of action & safety profile
Related Pipeline
FluoridePhase 3
Dental Caries
Combined Hepatitis A and B vaccinePhase 3
Hepatitis B
62.5/25mcgPhase 3
Pulmonary Disease, Chronic Obstructive
Losmapimod 7.5 mg twice dailyPhase 3
Acute Coronary Syndrome
GSK Biologicals' Meningococcal vaccine GSK134612 (Nimenrix)Phase 3
Infections, Meningococcal
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts